Navigation Links
Pharmion and MethylGene Announce Orphan Drug Designation Granted by the European Medicines Agency (EMEA) for MGCD0103 for the Treatment of Acute Myelogenous Leukemia
Date:2/11/2008

AML)

Acute myelogenous leukemia (AML) is a cancer of the blood and bone marrow that is characterized by the rapid proliferation (growth) of abnormal white blood cells. These cells are unable to perform their regular functions and eventually crowd out healthy red and white blood cells. Leukemia cells can also spread to other parts of the body. People afflicted with AML are susceptible to increased risk of infections, anemia and bleeding.

About 18,000 new cases of AML are diagnosed in Europe each year and the trend in overall incidence of AML has generally been stable or slowly increasing. AML is a rare form of cancer accounting for approximately 30 percent of all leukemias in the adult population and approximately 0.6 percent of all cancers. AML is estimated to affect less then two in 10,000 persons in the EU. The survival rate for AML at five years for adults under 55 is approximately 23 percent and for adults over 55 is approximately 10 percent.

Although several risk factors for AML have been identified, the specific cause of AML remains unclear. AML is a potentially curable disease; but only a minority of patients are cured with current therapies. Current treatments for AML include chemotherapy, blood transfusions and stem cell transplants.

About Pharmion

Pharmion is a leading global oncology company focused on acquiring, developing and commercializing innovative products for the treatment of hematology and oncology patients in the U.S., Europe and additional international markets. Pharmion has a number of products on the market including the world's first approved epigenetic drug, Vidaza(R), a DNA demethylating agent. For additional information about Pharmion, please visit the company's website at http://www.pharmion.com.

About MethylGene

MethylGene Inc. (TSX: MYG) is a publicly-traded biopharmaceutical company focused on the discovery, development and commerciali
'/>"/>

SOURCE Pharmion Corporation; MethylGene Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Pharmion and MethylGene Announce U.S. Orphan Drug Designation Granted for MGCD0103 for the Treatment of Hodgkins Lymphoma
2. Pharmion and MethylGene Initiate Phase One Combination Clinical Trial with MGCD0103 and Taxotere(R) in Patients with Solid Tumors
3. Pharmion Initiates Pivotal Phase 3 Study of Amrubicin in Small Cell Lung Cancer
4. Pharmion and MethylGene Report Preliminary MGCD0103 Clinical Data at the 2007 AACR-NCI-EORTC International Conference
5. Pharmions Amrubicin Shows Encouraging Results Compared to Standard of Care in Second Line Treatment of Small Cell Lung Cancer
6. Pharmion and MethylGene Start Phase 2 Combination Clinical Trial With MGCD0103 and Vidaza(R) in Patients With Relapsed or Refractory Hodgkin Lymphoma or Non-Hodgkin Lymphoma
7. Pharmion Submits European Marketing Authorization Application (MAA) for Vidaza(R) in Patients with Higher-Risk Myelodysplastic Syndromes (MDS)
8. Thalidomide Pharmion(R) Receives Positive Opinion for Treatment of First-line Multiple Myeloma from European Medicines Agency
9. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
10. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
11. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... SAN DIEGO , July 30, 2014 /PRNewswire/ ... held biotech company that designs and develops novel ... management of cancer, announced today the completion of ... The financing included new investors RusnanoMedInvest (RMI) and ... Fund, and Pfizer Venture Investments, as well as ...
(Date:7/30/2014)... , July 30, 2014 ... and CUDA programming expertise to big data, aerospace ... eInfochips, a leading engineering R&D services ... to develop NVIDIA GPU-powered solutions for aerospace ... high-performance computing (HPC), industrial , and ...
(Date:7/29/2014)... CAMBRIDGE, Mass. and HERZLIYA PITUACH, ... Inc. (OTCQX and NASDAQ OMX First North Premier, ... announces today that it has initiated the screening of ... trial exploring the safety and efficacy of bertilimumab in ... open-label trial will enroll 10-15 patients who will receive ...
Breaking Medicine Technology:Epic Sciences Announces Series C Financing to Advance Essential Cancer Diagnostics for Personalized Medicine 2Epic Sciences Announces Series C Financing to Advance Essential Cancer Diagnostics for Personalized Medicine 3eInfochips to Develop NVIDIA GPU-powered Solutions for Aerospace and Defense, Medical Imaging, HPC and Visual Computing 2Immune Pharmaceuticals Commences Patient Screening For Bertilimumab Phase II Clinical Trial In Bullous Pemphigoid, A Rare Auto-Immune Disease Of The Skin 2Immune Pharmaceuticals Commences Patient Screening For Bertilimumab Phase II Clinical Trial In Bullous Pemphigoid, A Rare Auto-Immune Disease Of The Skin 3Immune Pharmaceuticals Commences Patient Screening For Bertilimumab Phase II Clinical Trial In Bullous Pemphigoid, A Rare Auto-Immune Disease Of The Skin 4Immune Pharmaceuticals Commences Patient Screening For Bertilimumab Phase II Clinical Trial In Bullous Pemphigoid, A Rare Auto-Immune Disease Of The Skin 5
(Date:7/31/2014)... National non-profit World T.E.A.M. Sports’ annual Adventure ... 12-14, following two years in the high Colorado Plateau. ... and able-bodied athletes competing together in an inclusive outdoor ... experienced adventure athletes. , Hosted at the rustic ... River in the rugged Gore Mountains northwest of Vail, ...
(Date:7/31/2014)... July 31, 2014 In its latest blog ... and believes that having family close by during a stay ... not the process is successful, is looking at 10 tips ... , “Addiction recovery is a lifelong process, and one ... be committed to without compromise,” commented Best Drug Rehabilitation’s CEO ...
(Date:7/31/2014)... When guests shop CVS, they’ll find many ... Shea Moisture. And now CVS is adding another acclaimed brand ... 1, guests will find G Natural products in CVS stores ... CEO Roger Gore was inspired to start G’Natural Herbal Products ... developing a receding hairline; he tried many products on the ...
(Date:7/30/2014)... (PRWEB) July 31, 2014 Push to ... ninth annual national “Shop For A Cause” charity shopping ... Cause” is a unique one-day-only shopping event created to ... more than $44 million for charities across the country ... by purchasing shopping passes from Push to Walk now. ...
(Date:7/30/2014)... July 31, 2014 Responding to ... environment more responsive to an increasingly diverse patient ... experience and scholarly expertise to the publication of ... care professions: "Diversity and Cultural Competence in Health ... L. Dreachslin, PhD, a professor in the Management ...
Breaking Medicine News(10 mins):Health News:World T.E.A.M. Sports’ Adventure Team Challenge Returns to Colorado’s High Country 2Health News:World T.E.A.M. Sports’ Adventure Team Challenge Returns to Colorado’s High Country 3Health News:New Best Drug Rehabilitation Blog Posts Looks at 10 Tips for Coping After Drug or Alcohol Rehab 2Health News:CVS Caremark Adds New, Natural Acclaimed Hair Care Line to its Beauty Roster 2Health News:Push to Walk Participates in Macy’s Ninth Annual “Shop For A Cause” 2Health News:Push to Walk Participates in Macy’s Ninth Annual “Shop For A Cause” 3Health News:NLN CEO Co-Authors Textbook to Advance Diversity and Cultural Competence Across Health Care Professions 2Health News:NLN CEO Co-Authors Textbook to Advance Diversity and Cultural Competence Across Health Care Professions 3
... , , , LOUISVILLE, Ky., July ... regional provider of home health nursing services, announced today that it will ... on Wednesday, August 5, 2009, before the market open. , , ... 11:00 a.m. ET on August 5, 2009, and will be hosted by ...
... , WASHINGTON, July 31 Last ... Democratic leadership,s health care bill, H.R. 3200, that would specifically include ... of this bill. Family Research Council Action President Tony Perkins had ... Energy and Commerce Committee mark up: , , ...
... , , , , ... , HARRISBURG, Pa., July 31 Department of ... observance of National Immunization Awareness Month. , , ... sure you and your family are up-to-date on these immunizations is ...
... , , , ... statement by Jim O,Hara, Director, Produce Safety Project: , , ... the safety of fresh produce. The proposed guidance documents put out ... that the agency will finalize these documents quickly. We also look ...
... linked to headache, researchers explain , FRIDAY, July 31 ... cosmetic surgery, Michelle Cramer has now lost most of ... her frown lines. , Cramer, a graphics illustrator in ... close to a decade until she had surgery to ...
... , , , ABA program ... CALDWELL, N.J., July 31 Caldwell College will launch ... Analysis (ABA), a well developed scientific discipline that is best known ... disorder. Caldwell,s program was recently approved by the New Jersey ...
Cached Medicine News:Health News:Almost Family, Inc. to Report Second Quarter 2009 Financial Results on August 5, 2009 2Health News:House Measure Proves Healthcare Legislation Will Fund Abortion, Says Family Research Council Action 2Health News:Pennsylvania Secretary of Health Urges Pennsylvanians to Get Immunized 2Health News:Pennsylvania Secretary of Health Urges Pennsylvanians to Get Immunized 3Health News:Plastic Surgery Technique Might Ease Migraines 2Health News:Plastic Surgery Technique Might Ease Migraines 3Health News:Caldwell College Receives Approval to Launch First Ph.D. for Applied Behavior Analysis-Autism Treatment in New Jersey 2
... Merit Medical is pleased to offer ... The pre-coated, high-performance, InQwire guide wire ... is very lubricious and can help ... available in a wide range of ...
... The MULTI-LINK VISION Coronary Stent System ... of cobalt chromium stents. Cobalt chromium is ... so a cobalt chromium stent can have ... stainless steel stent with struts that are ...
BiodivYsio stent with biocompatible coating (phosphorylcholine)...
... The CYPHER Sirolimus-eluting Coronary ... antiproliferative drug, called "sirolimus", a ... stent delivery platform. Upon placement, ... wall and impedes the process ...
Medicine Products: